SEATTLE, Oct. 4, 2021 /PRNewswire/ -- Humedix, a subsidiary of Huons Global, has partnered with Kineta, an American biotechnology company to strengthen its CMO business and secure new drugs for future growth. Humedix CEO, Jinhwan Kim, announced that the company held a board of directors meeting on September 30th and agreed to sign a strategic equity investment agreement with Kineta, Inc., an immuno-oncology and antibody development company. Humedix will acquire a 1.56% stake in Kineta.
Humedix said it agreed with HLB Pharma on the exclusive license use and joint research and development concerning long-acting injections for obesity treatment at its headquarters in Pangyo, Gyeonggi Province, on Wednesday.